Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)

________________________________________________________

Department of Health and Human Services – Centers for Disease Control – NCIRD – Partnering with Professional and Medical Associations to Increase Vaccination Coverage Across Different Racial and Ethnic Adult Populations Experiencing Disparities

Proposal Due Date: January 19, 2021

Expected Number of Awards: 3

Estimated Total Program Funding: $1,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: CDC-RFA-IP21-2107

Purpose: DC seeks to build the evidence base of effective interventions to improve vaccination coverage and to identify and implement strategies to reduce racial and/or ethnic disparities in adult vaccination coverage. A strong recommendation from a healthcare provider is the single most important factor in vaccine acceptance as they are seen as trusted agents on vaccine-related issues for patients, especially if the provider is of the same racial or ethnic minority group as the patient. To improve vaccine confidence and coverage among certain racial and ethnic groups, CDC aims to increase the likelihood that providers, particularly providers of color, will recommend vaccination to patients from these racial and ethnic groups.

Develop strategies and resources for individual clinicians providing health care: Develop, implement, and disseminate strategies and resources to address clinicians’ roles in reducing racial and/or ethnic disparities in adult vaccination coverage (e.g., racial and health equity messaging, trainings, and materials)

Develop strategies and resources for health care organizations: Develop, implement, and disseminate strategies and resources to address the health care organizations’ role in reducing racial and/or ethnic disparities in adult vaccination coverage (e.g., recommended processes or practical guidance to members for improving equity in vaccine administration)

Enhance the resource and evidence base: Collaborate with the Learning Hub, Data Hub, and Media Center to review, modify, and improve resources

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Centers for Disease Control – NCCDPHP – Paul Coverdell National Acute Stroke Program

Proposal Due Date: March 18, 2021

Expected Number of Awards: 13

Estimated Total Program Funding: $23,100,000

Award Ceiling: $650,000

Award Floor: $500,000

Funding Opportunity Number: CDC-RFA-DP21-2102

Purpose: This NOFO will build upon accomplishments, outcomes achieved, and lessons learned through CDC-RFA-DP15-1514 by focusing efforts on implementing a state-wide registry, along with evidence-based strategies to measure, track, and improve access to and quality of care for those individuals at highest risk for stroke events and for stroke patients from onset of stroke symptoms through rehabilitation and recovery. These efforts must accurately identify disparities and then effectively address the relevant inequities including identification, assessment, and treatment across the continuum of care for those at highest risk for stroke events and for stroke patients.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Centers for Disease Control – ERA – Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)

Proposal Due Date: March 29, 2021

Expected Number of Awards: 5

Estimated Total Program Funding: $7,500,000

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: RFA-TS-21-001

Purpose: The Agency for Toxic Substances and Disease Registry (ATSDR) is seeking investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the National ALS Registry’s mission. The National ALS Registry’s goals are to estimate the number of new ALS cases each year, estimate the number of people who have ALS at a specific point in time, better understand who gets ALS, and identify what contributing factors, including environmental, may affect ALS. ATSDR is seeking investigator-initiated research that will identify and evaluate risk factors contributing to ALS, with preferred focus in this Notice of Funding Opportunity on factors related to military service, contact sports, traumatic brain injury, neuroinflammation and infectious agents.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Centers for Disease Control – ERA – The CDC National Centers of Excellence in Youth Violence Prevention (YVPCs): Rigorous Evaluation of Prevention Strategies to Prevent and Reduce Community Rates of Youth Violence

Proposal Due Date: April 21, 2021

Expected Number of Awards: 5

Estimated Total Program Funding: $30,000,000

Award Ceiling: $1,200,000

Award Floor:

Funding Opportunity Number: RFA-CE-21-005

Purpose: The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC or Injury Center) is soliciting research proposals to expand the evidence base for the primary prevention of youth violence. The purpose of this announcement is to fund the National Centers of Excellence in Youth Violence Prevention (Youth Violence Prevention Centers or YVPCs) to continue to build the evidence-base for violence prevention strategies and approaches that reduce community rates of youth violence within one or more geographically defined communities with high rates of youth violence. Applications for YVPCs supported under this announcement must describe 5 core elements: (1) an administrative infrastructure to support implementation, evaluation, and dissemination activities; to foster necessary local collaborations to achieve the YVPC’s goals; and to work with other funded YVPCs as part of the YVPC Network; (2) the selected community or set of communities with high rates of youth violence as the focus of all proposed YVPC activities; (3) a rigorous evaluation of at least two distinct prevention strategies related to at least two of the four research areas outlined in this NOFO that are designed to reduce community rates of youth violence in the selected community or set of communities; (4) a youth advisory council to provide input on the selection, implementation, and evaluation of youth violence prevention strategies; and (5) integrated training activities for early career and junior researchers in youth violence prevention to complement the implementation, rigorous evaluation, and scholarship activities of the YVPC.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Food and Drug Administration – Physiologically Based Pharmacokinetic (PBPK) Models of Oral Absorption to Simulate the Results of Bioequivalence Studies (U01) Clinical Trials Optional

Proposal Due Date: March 15, 2021

Expected Number of Awards: 2

Estimated Total Program Funding:

Award Ceiling: $600,000

Award Floor: $300,000

Funding Opportunity Number: RFA-FD-21-012

Purpose: Physiologically based pharmacokinetic (PBPK) models are an effective tool to integrate information about the product characteristics, the physiology of the individual subject, and the variability among subjects within a population to simulate the absorption and subsequent systemic disposition of the drug without conducting in vivo pharmacokinetic studies. These PBPK models have shown promise in supporting generic drug development and regulatory decision making. This opportunity solicits research proposals to expand the application of oral PBPK models to emerging issues in generic drug fields by providing the ability to simulate bioequivalence studies under various conditions.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Food and Drug Administration – Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Inhalation Products (U01) Clinical Trials Optional

Proposal Due Date: March 15, 2021

Expected Number of Awards: 2

Estimated Total Program Funding:

Award Ceiling: $400,000

Award Floor: $200,000

Funding Opportunity Number: RFA-FD-21-015

Purpose: Current U.S. Food and Drug Administration product-specific guidances for orally inhaled drug products such as metered dose inhalers (MDIs) and dry powder inhalers (DPIs) typically recommend using a weight-of-evidence approach for demonstrating bioequivalence (BE) that includes in vitro studies, an in vivo pharmacokinetics study, and either an in vivo pharmacodynamics or comparative clinical endpoint BE study. To produce a generic MDI or DPI that can meet acceptance criteria from all these recommended studies, it would be useful to have an enhanced understanding of the relationships between in vitro study metrics and the rate and extent of drug delivery to the targeted lung tissue. Computational fluid dynamics (CFD) is a technique capable of predicting these relationships between in vitro study metrics and regional lung deposition. The purpose of this funding opportunity announcement is to use CFD to produce verified and validated predictions of regional lung deposition for at least one currently marketed MDI or DPI in human upper and lower airways and to develop an in vitro-in vivo correlation (IVIVC) between model predictions and at least one relevant in vitro metric. Generic drug developers may then use this IVIVC to interpret in vitro results in a manner that may increase confidence in their products prior to in vivo testing

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Food and Drug Administration – Quantify the expression of metabolizing enzymes and transporter proteins in lung, eye and skin tissue in relevant animal models and humans (U01) Clinical Trial Not Allowed

Proposal Due Date: March 15, 2021

Expected Number of Awards: 5

Estimated Total Program Funding:

Award Ceiling: $850,000

Award Floor: $300,000

Funding Opportunity Number: RFA-FD-21-019

Purpose: The purpose of this funding opportunity is to systematically quantify the protein levels of potential metabolizing enzymes and transporters in rabbit and human eye tissue, human lung tissue, and human skin tissue using most advanced techniques, where individual proposals will select one research area (i.e., ophthalmic, dermal, or pulmonary). Subsequently, the experimental data collected from this study will be implemented into existing modeling platforms to allow for virtual bioequivalence (BE) assessments locally and systemically for the parent and pharmacologically active metabolite.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Health Resources and Services Administration – Emerging Issues in Maternal and Child Health

Proposal Due Date: April 9, 2021

Expected Number of Awards: 6

Estimated Total Program Funding: $1,500,000

Award Ceiling: $250,000

Award Floor:

Funding Opportunity Number: HRSA-21-080

Purpose: This notice announces the opportunity to apply for funding under the Emerging Issues in Maternal and Child Health Program. The purpose of this program is to strengthen the capacities of state- and/or local-level organizations to respond to emerging public health issues affecting maternal and child health (MCH) populations.

This funding opportunity is a mechanism to support capacity-strengthening activities that will improve state- and/or local-level organizations’ abilities to address emerging issues that threaten the health and well-being of MCH populations in an effective, timely manner. For the purposes of this NOFO, MCH populations include the following groups: women, children (birth to 21), children with special health care needs (CSHCN), adolescents, and families.

Recipients will implement a set of activities under at least one of the three capacity-strengthening areas below (See Section IV.2 for details) and through these activities address an emerging issue specific to their state or local community.

Capacity Areas:

1) Data and Informational Systems

2) Workforce Development

3) Strategic Partnerships

“Emerging issues” refers to issues that affect MCH populations at an increased rate, for which there is new knowledge or an increased level of awareness of, or there are new approaches to solving the issue. The challenge is that these issues are difficult to anticipate and thus difficult for which to have funds set aside. Through this program, the HRSA Maternal and Child Health Bureau (MCHB) aims to increase the ability of states and local communities to anticipate, prepare, and execute timely responses to emerging issues to reduce their negative impact on MCH populations.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – Health Resources and Services Administration – Rural Communities Opioid Response Program-Psychostimulant Support

Proposal Due Date: April 12, 2021

Expected Number of Awards: 15

Estimated Total Program Funding: $7,500,000

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: HRSA-21-091

Purpose: The Rural Communities Opioid Response Program (RCORP) is a multi-year initiative by the Health Resources and Services Administration (HRSA) aimed at reducing the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in high risk rural communities. This notice announces the opportunity to apply for funding under RCORP-Psychostimulant Support (RCORP-PS). RCORP-PS will advance RCORP’s overall goal by strengthening and expanding prevention, treatment, and recovery services for rural individuals who misuse psychostimulants to enhance their ability to access treatment and move towards recovery.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinsons Disease (U01 Clinical Trial Not Allowed)

Letter of Intent Due Date: May 22, 2021

Proposal Due Date: March 15, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $2,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-NS-21-017

Purpose: This FOA seeks applications to perform single nucleus RNA sequencing (snRNA seq) and whole genome sequencing (WGS) in post-mortem brain tissue from 100 patients with PD and normal controls for the Accelerating Medicine Partnership in Parkinson’s Disease (AMP PD). Applicants will be expected to have access to high quality brain tissue and perform sequencing in four separate brain regions, including some regions known to be affected by Parkinson’s Disease (PD) and at least one region known to be relatively spared. It is intended that all sequencing data and any available pre-mortem clinical data will be broadly shared with the research community through the AMP PD Knowledge Portal.

View more details on this opportunity.

____________________________________________________            

Department of Health and Human Services – National Institutes of Health – Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)

Letter of Intent Due Date: February 15, 2021

Proposal Due Date: March 15, 2021

Expected Number of Awards: 8

Estimated Total Program Funding: $6,240,000

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: RFA-HL-21-014

Purpose:  This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus (T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 Clinical Trial Optional)

Letter of Intent Due Date: February 15, 2021

Proposal Due Date: March 15, 2021

Expected Number of Awards: 8

Estimated Total Program Funding: $6,240,000

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: RFA-HL-21-014

Purpose:  The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.  The focus of this FOA is on macrovascular disease that includes outcomes of myocardial infarction, stroke, peripheral artery disease, heart failure, cardiomyopathy, cardiac arrythmias and cardiac autonomic neuropathy and/or the study of coronary arteries, cerebral arteries, large peripheral arteries, cardiac tissue, atherosclerosis, thrombosis and lipoprotein metabolism. Research can include the effect of microvascular disease on the development of macrovascular disease, e.g., DKD, but the emphasis must be on CVD.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer’s Disease (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date: February 18, 2021

Proposal Due Date: March 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-AG-21-033

Purpose: This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)

Letter of Intent Due Date: February 18, 2021

Proposal Due Date: March 18, 2021

Expected Number of Awards:

Estimated Total Program Funding: $2,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-MH-21-145

Purpose: As part of NIHs Helping to End Addiction Long Term (HEAL) Initiative, this RFA invites research that will optimize multi-component service delivery interventions for people with opioid use disorder and co-occurring conditions, to include suicide risk. The purpose of the initiative is to support studies that will test (1) overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness. This research will streamline service packages so they only include components that drive clinical improvements for complex conditions. Studies are to be highly pragmatic and practice relevant, with designs that balance rigor with time-to-practice urgency. Projects will seek to a) identify constitute components that drive improvements in access, continuity, quality, value, and outcomes of care, for service delivery interventions with previously demonstrated effectiveness as a bundled package; and b) simultaneously test overall effectiveness of the package and its subcomponents, for popular (widely implemented) service delivery packages without previously demonstrated effectiveness.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial – Clinical Sites (UG1 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 30, 2021

Expected Number of Awards: 15-20

Estimated Total Program Funding: $5,000,000

Award Ceiling: $150,000

Award Floor:

Funding Opportunity Number: RFA-DA-21-031

Purpose: This FOA invites applications for Clinical Centers to design and implement a multi-center, comparative effectiveness, randomized controlled trial (RCT) to assess the optimal pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS).

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: Data Coordinating Center for the Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial (U24 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 30, 2021

Expected Number of Awards:

Estimated Total Program Funding: $2,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DA-21-032

Purpose: This FOA invites applications for a Data Coordinating Center (DCC) to design and implement a multi-center, comparative effectiveness, randomized controlled trial (RCT) to assess the optimal pharmacological treatment for Neonatal Opioid Withdrawal Syndrome (NOWS).

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: March 31, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $575,000

Award Ceiling: $575,000

Award Floor:

Funding Opportunity Number: RFA-DA-21-029

Purpose: The National Institutes of Health (NIH) intends to establish a Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) network consisting of clinical research centers, which will be supported by a single Coordination and Dissemination center. This network is intended to create multidisciplinary team science collaborations to develop effective interventions, best models of care for delivery of services, and sustainable implementation strategies for access to quality care for complex patients with chronic pain (CP) and opioid use disorder (OUD) or opioid misuse. The network will be part of the NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management.

View more details on this opportunity.

____________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)

Proposal Due Date: March 31, 2021

Expected Number of Awards:

Estimated Total Program Funding: $7,250,000

Award Ceiling: $1,750,000

Award Floor:

Funding Opportunity Number: RFA-DA-21-030

Purpose: Chronic Non-Cancer Pain (CP) and Opioid Use Disorder (OUD) overlap significantly and patients with both conditions present particular clinical complexity. CP adversely impacts OUD treatment adherence and recovery, while the presence of dependence stigmatizes treatment services for chronic pain, often resulting in insufficient pain treatment. Fundamentally, the healthcare system lacks the expertise and effective interventions for managing comorbid CP and OUD, leaving patients suffering and at risk for poor outcomes. The National Institutes of Health (NIH) intends to establish a national network consisting of investigators conducting Collaborative research on Co-managing Chronic Pain and Opioid Use Disorder (C3PO), which will be supported by a Resource on Related DSM-5 Diagnoses (R2D2) Coordination and Dissemination center. This network is intended to facilitate multidisciplinary team science collaborations that can create actionable, translatable, and sustainable treatments to improve the capacity of the health care system to effectively respond to the opioid epidemic. The network will be part of the NIHs Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed)

Letter of Intent Due Date: March 1, 2021

Proposal Due Date: March 31, 2021

Estimated Total Program Funding: $26,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DA-21-020

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for linked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This FOA runs in parallel with companion FOAs that seek applications for single, unlinked Research Project Sites (RFA-DA-21-021), a single Consortium Administrative Core (RFA-DA-21-022) and a single Data Coordinating Center (RFA-DA-21-023). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. This FOA seeks applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.

View more details on this opportunity.

____________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: HEALthy Brain and Child Development Study (U01 – Clinical Trial Not Allowed)

Letter of Intent Due Date: March 1, 2021

Proposal Due Date: March 31, 2021

Estimated Total Program Funding: $26,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DA-21-021

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for unlinked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This FOA runs in parallel with companion FOAs that seek applications for linked Research Project Sites (RFA-DA-21-020), a single Consortium Administrative Core (RFA-DA-21-022) and a single Data Coordinating Center (RFA-DA-21-023). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. This FOA seeks applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: HEALthy Brain and Child Development Consortium Administrative Core (U24 – Clinical Trial Not Allowed)

Letter of Intent Due Date: March 1, 2021

Proposal Due Date: March 31, 2021

Expected Number of Research Sites Funded:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DA-21-022

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. This FOA runs in parallel with companion FOAs that seek applications for linked (RFA-DA-21-020) and unlinked (RFA-DA-21-021) research sites and a single Data Coordinating Center (RFA-DA-21-023). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. The HBCD Consortium Administrative Core (HCAC) will be responsible for providing the organizational framework for the management, direction, and overall coordination of the national multi-site consortium. It will coordinate the interactions of the individual Research Project Sites and the HBCD Data Coordinating Center. The Consortium Administrative Core will include Administrative and Project Management Plans, and will also be responsible for managing collaborative activities such as the functions of an Expert Scientific Board and oversight of an internal Steering Committee. See Section I (Funding Opportunity Description) below for more information.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – HEAL Initiative: HEALthy Brain and Child Development Data Coordinating Center (U24)

Letter of Intent Due Date: March 1, 2021

Proposal Due Date: March 31, 2021

Expected Number of Research Sites Funded:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DA-21-023

Purpose: The NIH Helping to End Addiction Long-termSM (HEAL) Initiative and the National Institute on Drug Abuse (NIDA), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), the Office of Behavioral and Social Sciences Research (OBSSR), the Office of Research on Womens Health (ORWH), the National Institute of Environmental Health Sciences (NIEHS), the National Institute on Minority Health and Health Disparities (NIMHD), and the Environmental influences on Child Health Outcomes (ECHO) Program, intend to jointly fund the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This Funding Opportunity Announcement (FOA) solicits applications for a Data Coordinating Center. This FOA runs in parallel with companion FOAs that solicit applications for research project sites (RFA-DA-21-020 and RFA-DA-21-021) and a single Consortium Administrative Core (RFA-DA-21-022). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Limited Competition: Revision to the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: April 14, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-DK-20-508

Purpose: Type 1 diabetes (T1D) is a serious and burdensome chronic disease that usually onsets in childhood or early adulthood. Recent progress in clinical trials and understanding of T1D pathogenesis and mechanisms have created opportunities to delay the onset and progression of the disease. This supplement is intended to provide resources for the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D through the T1D TrialNet network (TrialNet). This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the TrialNet Coordinating Center (TNCC) that is currently supporting the research being performed by TrialNet. The TNCC provides TrialNet with scientific leadership in study design and monitoring, supports the clinical and laboratory testing for the conduct of trials, and supports systems for data collection, processing, biostatistical analyses and administrative operations.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)

Proposal Due Date: May 7, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAS-21-031

Purpose: This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed)

Letter of Intent Due Date: 30 days prior to application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $600,000

Award Floor:

Funding Opportunity Number: RFA-AI-21-001

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

View more details on this opportunity.

________________________________________________________

Department of Health and Human Services – National Institutes of Health – Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)

Letter of Intent Due Date: May 22, 2021

Proposal Due Date: June 22, 2021

Expected Number of Awards: 2

Estimated Total Program Funding: $675,000

Award Ceiling: $225,000

Award Floor:

Funding Opportunity Number: RFA-DK-20-032

Purpose: The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

View more details on this opportunity.

____________________________________________________

Department of Health and Human Services – Substance Abuse and Mental Health Services Administration –  National Child Traumatic Stress Initiative – Category II, Treatment and Service Adaptation (TSA) Centers

Proposal Due Date: February 22, 2021

Expected Number of Awards: 35

Estimated Total Program Funding: $24,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: SM-21-009

Purpose: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services (CMHS), is accepting applications for fiscal year (FY) 2021 National Child Traumatic Stress Initiative (NCTSI) – Category II, Treatment and Service Adaptation (TSA) Centers (Short Title: NCTSI-II). The purpose of the TSA Centers is to provide national expertise for specific types of traumatic events, population groups, and service systems, and support the specialized adaptation of effective evidence-based treatment and service approaches for communities across the nation.

View more details on this opportunity.